---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-029960"
form_type: "8-K"
ticker: "IONS"
cik: "0000874015"
company_name: "IONIS PHARMACEUTICALS INC"
filed_at: "2026-07-29T11:31:02+00:00"
generated_at: "2026-07-29T11:35:18.399650+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ionis Q2 2026 revenue $268M, operating loss $102M; eplontersen misses ATTR-CM endpoint

## Summary
- Total revenue $268M (down 41% YoY); excluding one-time sapablursen payment, revenue up 56% YoY.
- Operating loss from operations $102M vs income $140M in Q2 2025; non-GAAP operating loss $57M.
- TRYNGOLZA net sales $5M in Q2, $32M in H1; DAWNZERA net sales $26M in Q2, $42M in H1.
- Eplontersen CARDIO-TTRansform missed primary composite endpoint in overall population; nominal significance in monotherapy.
- Zilganersen NDA under FDA Priority Review with PDUFA Sept 22, 2026; on track for launch this year.

## SEC filing metadata
- accession: 0001140361-26-029960
- form_type: 8-K
- ticker: IONS
- cik: 0000874015
- company_name: IONIS PHARMACEUTICALS INC
- filed_at: 2026-07-29T11:31:02+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/874015/000114036126029960/0001140361-26-029960-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874015/000114036126029960/ef20078953_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-029960
- JSON: https://secwatch.observer/filing/0001140361-26-029960.json
- Plain text: https://secwatch.observer/filing/0001140361-26-029960.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.